| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRC.2017.7 |
| P698 | PubMed publication ID | 28233803 |
| P50 | author | James D Brenton | Q30506432 |
| Jonathan C M Wan | Q88226723 | ||
| Florent Mouliere | Q41134950 | ||
| Richard Baird | Q42878560 | ||
| P2093 | author name string | Carlos Caldas | |
| Charles Massie | |||
| Simon Pacey | |||
| Nitzan Rosenfeld | |||
| Javier Garcia-Corbacho | |||
| P2860 | cites work | Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model. | Q51392988 |
| Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: A qualitative study. | Q51696252 | ||
| Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy. | Q51836356 | ||
| Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer. | Q51898098 | ||
| Real-time, portable genome sequencing for Ebola surveillance | Q24283957 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) | Q24635921 | ||
| Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations | Q24678861 | ||
| Digital PCR | Q24685020 | ||
| Non-invasive prenatal testing: a review of international implementation and challenges | Q26999426 | ||
| Fragment Length of Circulating Tumor DNA | Q27308628 | ||
| Long-term dual-color tracking of genomic loci by modified sgRNAs of the CRISPR/Cas9 system. | Q27324149 | ||
| Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. | Q27853162 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer | Q28079253 | ||
| Double-stranded DNA in exosomes: a novel biomarker in cancer detection | Q28237711 | ||
| Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma | Q28261810 | ||
| Development of personalized tumor biomarkers using massively parallel sequencing | Q28278819 | ||
| Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing | Q28280303 | ||
| Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers | Q28282973 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence | Q28385712 | ||
| Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer | Q28390093 | ||
| Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma | Q28601304 | ||
| FAST-SeqS: a simple and efficient method for the detection of aneuploidy by massively parallel sequencing | Q28729073 | ||
| Winnowing DNA for rare sequences: highly specific sequence and methylation based enrichment | Q28732084 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Origins, structures, and functions of circulating DNA in oncology | Q30249103 | ||
| Detection and quantification of rare mutations with massively parallel sequencing | Q30472217 | ||
| Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. | Q36145554 | ||
| Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. | Q36185551 | ||
| Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing | Q36188885 | ||
| Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study | Q36229421 | ||
| Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study. | Q36233925 | ||
| Noninvasive monitoring of infection and rejection after lung transplantation | Q36238500 | ||
| RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics | Q36278318 | ||
| Serum tumor markers in breast cancer: are they of clinical value? | Q36367261 | ||
| Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin | Q36468959 | ||
| Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma | Q36561655 | ||
| Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations | Q36580836 | ||
| Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients | Q36586155 | ||
| Reversible acetylation on Lys501 regulates the activity of RNase II | Q36701131 | ||
| Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance | Q36719984 | ||
| Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. | Q36745519 | ||
| Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance | Q36764022 | ||
| Identification of tissue-specific cell death using methylation patterns of circulating DNA | Q36770646 | ||
| Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors | Q36815383 | ||
| Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. | Q36865058 | ||
| Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay | Q36962764 | ||
| Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. | Q36998629 | ||
| Exposure to low-dose ionizing radiation from medical imaging procedures | Q36999610 | ||
| Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. | Q37000646 | ||
| Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. | Q37206520 | ||
| A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis | Q37221407 | ||
| Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. | Q37281253 | ||
| Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer | Q37307603 | ||
| Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment | Q37401069 | ||
| Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer | Q37638241 | ||
| Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. | Q37646889 | ||
| Circulating cell free DNA: Preanalytical considerations | Q38111116 | ||
| Cellular barcoding: a technical appraisal. | Q38226367 | ||
| Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer | Q38275060 | ||
| Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments | Q30667824 | ||
| Real-time selective sequencing using nanopore technology | Q30806794 | ||
| MinION Analysis and Reference Consortium: Phase 1 data release and analysis | Q31042112 | ||
| Circulating DNA and DNase activity in human blood | Q33263721 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Detection of cancer DNA in plasma of patients with early-stage breast cancer. | Q33624889 | ||
| Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. | Q33663019 | ||
| Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia | Q33850554 | ||
| Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. | Q33851726 | ||
| High fragmentation characterizes tumour-derived circulating DNA. | Q34016528 | ||
| Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer | Q34039531 | ||
| About the possible origin and mechanism of circulating DNA apoptosis and active DNA release | Q34100424 | ||
| Identification of p53 gene mutations in bladder cancers and urine samples | Q34104561 | ||
| Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts | Q34117027 | ||
| Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 | ||
| Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. | Q34139666 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury | Q34224506 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| Detection of ultra-rare mutations by next-generation sequencing | Q34291814 | ||
| The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. | Q34317490 | ||
| Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. | Q34322575 | ||
| A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. | Q34351104 | ||
| Novel electrophoresis mechanism based on synchronous alternating drag perturbation | Q34380432 | ||
| Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing | Q34382581 | ||
| Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors | Q34386166 | ||
| First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. | Q34386915 | ||
| Rapid clearance of fetal DNA from maternal plasma | Q34388637 | ||
| Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. | Q34411556 | ||
| Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas | Q34421199 | ||
| Spatial and temporal diversity in genomic instability processes defines lung cancer evolution | Q34442770 | ||
| Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform | Q34457501 | ||
| Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types | Q34457638 | ||
| High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing | Q34464967 | ||
| Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. | Q53191487 | ||
| Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. | Q53407197 | ||
| Plasma AR and abiraterone-resistant prostate cancer. | Q53810482 | ||
| The clearance and localization of nucleic acids by New Zealand and normal mice | Q54028911 | ||
| The cancer bloodhounds. | Q54459424 | ||
| Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. | Q54593981 | ||
| Noninvasive prenatal testing by nanopore sequencing of maternal plasma DNA: feasibility assessment. | Q55059264 | ||
| PCR-detection of tumor-derived p53 DNA in cerebrospinal fluid. | Q55480921 | ||
| Free DNA in the serum of cancer patients and the effect of therapy. | Q55492005 | ||
| Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus | Q56937251 | ||
| TP53andKRAS2Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study | Q57037815 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Cellular Uptake of Deoxyribonucleic Acid by Human Tissue Culture Cells | Q58937907 | ||
| Changes in Concentration of DNA in Serum and Plasma during Storage of Blood Samples | Q62632521 | ||
| Measurement of deoxyribonuclease I activity in human tissues and body fluids by a single radial enzyme-diffusion method | Q70598645 | ||
| Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia | Q72018776 | ||
| Plasma collected from heparinized blood is not suitable for HCV-RNA detection by conventional RT-PCR assay | Q72085813 | ||
| Soluble normal and mutated DNA sequences from single-copy genes in human blood | Q72268467 | ||
| Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA) | Q72800053 | ||
| Prenatal DNA diagnosis of a single-gene disorder from maternal plasma | Q73074402 | ||
| Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis | Q73121380 | ||
| Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation | Q77678904 | ||
| Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation | Q79362886 | ||
| Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer | Q81186156 | ||
| The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke | Q82734214 | ||
| Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing | Q86102976 | ||
| Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer | Q87567670 | ||
| Direct measurement of cell-free DNA from serially collected capillary plasma during incremental exercise | Q87981791 | ||
| ??? | Q94720111 | ||
| BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System | Q38380202 | ||
| Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma | Q38384301 | ||
| Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. | Q38390966 | ||
| Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial | Q38407938 | ||
| Sense and nonsense in the process of accreditation of a pathology laboratory | Q38579544 | ||
| Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. | Q38771051 | ||
| Metastasis as an evolutionary process | Q38819909 | ||
| The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics | Q38821212 | ||
| Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. | Q38821392 | ||
| Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. | Q38839797 | ||
| Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor | Q38880070 | ||
| Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach. | Q38884073 | ||
| DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment | Q39230177 | ||
| Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA. | Q39344296 | ||
| Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer | Q39488839 | ||
| Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma | Q39534880 | ||
| ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study | Q39549460 | ||
| Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients | Q39877158 | ||
| Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care | Q40022390 | ||
| Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer | Q40069057 | ||
| Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. | Q40130589 | ||
| Brain tumor mutations detected in cerebral spinal fluid | Q40251034 | ||
| Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. | Q40255202 | ||
| PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients | Q40261157 | ||
| Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma | Q40288940 | ||
| EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. | Q40324544 | ||
| Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer | Q40364937 | ||
| Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. | Q40370392 | ||
| Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. | Q40372621 | ||
| Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients | Q40374512 | ||
| Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. | Q40454933 | ||
| Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes. | Q40564903 | ||
| Nanopore sequencing detects structural variants in cancer. | Q40720413 | ||
| Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing | Q41134756 | ||
| Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer | Q41134871 | ||
| Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer | Q41260159 | ||
| Use of research biopsies in clinical trials: are risks and benefits adequately discussed? | Q41264496 | ||
| Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer | Q41646881 | ||
| Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology | Q41821680 | ||
| Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. | Q41868457 | ||
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. | Q42183079 | ||
| Pros: Can tissue biopsy be replaced by liquid biopsy? | Q42398704 | ||
| Commentary on tumor heterogeneity | Q42398711 | ||
| Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade | Q42690704 | ||
| Inferring expressed genes by whole-genome sequencing of plasma DNA. | Q42774378 | ||
| Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells | Q42830431 | ||
| Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing | Q43118556 | ||
| Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. | Q43166831 | ||
| A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma | Q43515871 | ||
| DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. | Q43540280 | ||
| A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative | Q43763245 | ||
| Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program | Q44554229 | ||
| Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing | Q44576396 | ||
| Origin and prognostic value of circulating KRAS mutations in lung cancer patients | Q45017062 | ||
| Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma | Q45721923 | ||
| Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. | Q45993942 | ||
| Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients | Q46448121 | ||
| Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells. | Q46636377 | ||
| Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls | Q47831743 | ||
| Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. | Q48020812 | ||
| Co-occurrence of MYC amplification and TP53 mutations in human cancer | Q48253543 | ||
| Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer | Q48655131 | ||
| The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. | Q50276908 | ||
| Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. | Q50607902 | ||
| Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. | Q51038461 | ||
| Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status | Q34473831 | ||
| Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol | Q34480344 | ||
| Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies | Q34484712 | ||
| Rapid Short-Read Sequencing and Aneuploidy Detection Using MinION Nanopore Technology | Q34499358 | ||
| Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer | Q34500359 | ||
| Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) | Q34515855 | ||
| Integrated digital error suppression for improved detection of circulating tumor DNA | Q34520008 | ||
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Q34533164 | ||
| Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 | ||
| Single-stranded DNA library preparation for the sequencing of ancient or damaged DNA. | Q34620490 | ||
| MicroRNAs accurately identify cancer tissue origin | Q34764379 | ||
| Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing | Q34769683 | ||
| Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib | Q35004426 | ||
| Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. | Q35078413 | ||
| Direct quantification of cell-free, circulating DNA from unpurified plasma | Q35111355 | ||
| Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. | Q35127938 | ||
| Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors | Q35132293 | ||
| Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. | Q35133788 | ||
| Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients | Q35212779 | ||
| Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment | Q35218647 | ||
| Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells | Q35664110 | ||
| Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin | Q35752935 | ||
| Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer | Q35789737 | ||
| Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA | Q35810461 | ||
| Subclonal diversification of primary breast cancer revealed by multiregion sequencing | Q35847434 | ||
| Ultrasensitive Detection of Multiplexed Somatic Mutations Using MALDI-TOF Mass Spectrometry | Q35848882 | ||
| Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer | Q35879064 | ||
| Digital PCR for the molecular detection of fetal chromosomal aneuploidy | Q35916813 | ||
| Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord | Q35946342 | ||
| Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease | Q36000803 | ||
| Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations | Q36077810 | ||
| Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration | Q36087929 | ||
| Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients | Q36104839 | ||
| Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening. | Q36112242 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biopsy | Q179991 |
| liquid | Q11435 | ||
| P304 | page(s) | 223-238 | |
| P577 | publication date | 2017-02-24 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Liquid biopsies come of age: towards implementation of circulating tumour DNA. | |
| P478 | volume | 17 |
| Q42059581 | 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. |
| Q64980091 | 5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer. |
| Q91739217 | 6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage |
| Q98771618 | A New Method for CTC Images Recognition Based on Machine Learning |
| Q61448076 | A Novel Multifunctional Nanowire Platform for Highly Efficient Isolation and Analysis of Circulating Tumor-Specific Markers |
| Q93098986 | A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors |
| Q99350269 | A biocomposite-based rapid sampling assay for circulating cell-free DNA in liquid biopsy samples from human cancers |
| Q93163843 | A catalogue of cancer-driving mutations in healthy tissue |
| Q64098205 | A comparison of mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients |
| Q46280012 | A conduit to metastasis: circulating tumor cell biology |
| Q89764960 | A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA) |
| Q55028022 | A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection. |
| Q48178985 | A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications |
| Q54116418 | A liquid biopsy in primary lung cancer. |
| Q64990558 | A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. |
| Q91272659 | A view on drug resistance in cancer |
| Q64880993 | ASO Author Reflections: Advanced Imaging Allows Better Detection of Peritoneal Metastases. |
| Q92876654 | Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples |
| Q91606820 | Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose |
| Q103836778 | Advances in bladder cancer biology and therapy |
| Q49502117 | Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis. |
| Q99709797 | Advances in the assessment of minimal residual disease in mantle cell lymphoma |
| Q64093267 | Analysis of error profiles in deep next-generation sequencing data |
| Q91646745 | Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma |
| Q53078885 | Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. |
| Q92853277 | Application of Microfluidic Chips in Separation and Analysis of Extracellular Vesicles in Liquid Biopsy for Cancer |
| Q64117640 | Application of circulating tumor DNA for dynamic monitoring of advanced non-small cell lung cancer treatment response: An open-label, multicenter, prospective, observational study protocol |
| Q96111349 | Application of liquid biopsy for surgical management of pancreatic cancer |
| Q62490912 | Artificial intelligence in cancer imaging: Clinical challenges and applications |
| Q89790106 | Assessing aneuploidy with repetitive element sequencing |
| Q92572720 | Assessment of clinical performance of an ultrasensitive nanowire assay for detecting human papillomavirus DNA in urine |
| Q91695615 | Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer |
| Q55415624 | Bamgineer: Introduction of simulated allele-specific copy number variants into exome and targeted sequence data sets. |
| Q64057678 | Basics and applications of tumor-derived extracellular vesicles |
| Q92582560 | Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer |
| Q97904858 | Bioactive DNA from extracellular vesicles and particles |
| Q92852968 | Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer |
| Q64102563 | Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology |
| Q42360040 | Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer |
| Q58707823 | Biomarkers for hepatocellular carcinoma: What's new on the horizon? |
| Q57152715 | Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma |
| Q90788586 | Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab |
| Q45943221 | Breast cancer: The translation of big genomic data to cancer precision medicine. |
| Q33730180 | CVE: an R package for interactive variant prioritisation in precision oncology. |
| Q48247046 | Can circulating tumor DNA be used for direct and early stage cancer detection? |
| Q89622170 | Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach? |
| Q55692870 | Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. |
| Q64899552 | Cancer detection: Seeking signals in blood. |
| Q90664772 | Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling |
| Q59137752 | Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations |
| Q64245475 | Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer |
| Q99238734 | Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer |
| Q91809276 | Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study |
| Q89842618 | Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer |
| Q98945182 | Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations |
| Q58113203 | Cell-free DNA in cancer: current insights |
| Q92005579 | Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study |
| Q58107792 | Cell-free DNA release under psychosocial and physical stress conditions |
| Q50079099 | Cell-free DNA: Treasure trove for cancer medicine |
| Q90086642 | Cell-free tumor DNA: Emerging reality in oral squamous cell carcinoma |
| Q52721890 | Centrifugation-free extraction of circulating nucleic acids using immiscible liquid under vacuum pressure. |
| Q41605016 | Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer |
| Q91410839 | Challenges to curing primary brain tumours |
| Q55317074 | Characterization and remediation of sample index swaps by non-redundant dual indexing on massively parallel sequencing platforms. |
| Q46087686 | Cholangiocarcinoma - evolving concepts and therapeutic strategies |
| Q58114470 | Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review |
| Q64994294 | Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. |
| Q90645875 | Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma |
| Q55260471 | Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. |
| Q93200678 | Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review |
| Q90604965 | Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis |
| Q58096215 | Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies |
| Q57166936 | Circulating Tumour DNA in Muscle-Invasive Bladder Cancer |
| Q52601844 | Circulating cell-free DNA for non-invasive cancer management. |
| Q54983901 | Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression. |
| Q90664794 | Circulating miRNAs as Biomarker in Cancer |
| Q47121916 | Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer |
| Q55282878 | Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). |
| Q101121128 | Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients |
| Q64981121 | Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. |
| Q58704645 | Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors |
| Q95260253 | Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort |
| Q89359764 | Circulating tumor DNA dynamically predicts response and/or relapse in patients with hematological malignancies |
| Q99603571 | Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response |
| Q62644766 | Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity |
| Q87930863 | Circulating tumor DNA measurement provides reliable mutation detection in mice with human lung cancer xenografts |
| Q92147413 | Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma |
| Q45330204 | Circulating tumor DNA: Solid data from liquid biopsies. |
| Q96019155 | Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma |
| Q89521103 | Circulating tumour DNA in early stage colorectal cancer: can blood tell all? |
| Q47562193 | Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. |
| Q90216774 | Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors |
| Q92026475 | Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma |
| Q89921665 | Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer |
| Q90614025 | Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience |
| Q99616869 | Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond |
| Q64084978 | Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors |
| Q61455455 | Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer |
| Q48277300 | Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. |
| Q61808912 | Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma |
| Q58607569 | Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors |
| Q89521179 | Clonal hematopoiesis: background player in plasma cell-free DNA variants |
| Q47608030 | Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany. |
| Q47167930 | Comparative analysis of 12 different kits for bisulfite conversion of circulating cell-free DNA. |
| Q90117978 | Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR |
| Q92993950 | Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq) |
| Q89945283 | Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors |
| Q59801659 | Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease |
| Q64263552 | Considerations and quality controls when analyzing cell-free tumor DNA |
| Q91977826 | Controlling DNA Translocation Through Solid-state Nanopores |
| Q41524917 | Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients |
| Q91830988 | Current and emerging biomarkers in metastatic colorectal cancer |
| Q58586693 | Current and future perspectives of liquid biopsies in genomics-driven oncology |
| Q97545892 | DNA methylation biomarkers of future health outcomes in children |
| Q89667079 | DNA methylation changes in biomarker loci occur early in cancer progression |
| Q47299130 | DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA. |
| Q97419469 | Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing |
| Q92424076 | Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect |
| Q64100601 | Designing circulating tumor DNA-based interventional clinical trials in oncology |
| Q64255946 | Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease |
| Q89669623 | Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives |
| Q64899007 | Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). |
| Q90354804 | Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors |
| Q58606619 | Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients |
| Q54935962 | Detection of circulating tumor DNA for advanced bladder cancer: where are we going? |
| Q93006316 | Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment |
| Q91069398 | Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group |
| Q96028455 | Detection of ctDNA with Personalized Molecular Barcode NGS and Its Clinical Significance in Patients with Early Breast Cancer |
| Q57288274 | Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy |
| Q100503891 | Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing |
| Q93120560 | Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing |
| Q38716377 | Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma |
| Q88736846 | Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma |
| Q64080463 | Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples |
| Q52652196 | Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. |
| Q89727336 | Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer |
| Q89519073 | Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis |
| Q64068854 | Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma |
| Q93010786 | Digital Droplet PCR for Monitoring Tissue-Specific Cell Death Using DNA Methylation Patterns of Circulating Cell-Free DNA |
| Q48528638 | Discovery of Double-Stranded Genomic DNA in Circulating Exosomes |
| Q48521971 | Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. |
| Q89882519 | Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma |
| Q50043988 | Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study |
| Q55334265 | Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer. |
| Q91405316 | Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer |
| Q91438831 | Early detection of the PAX3-FOXO1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma |
| Q89400755 | Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection |
| Q58702496 | Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients |
| Q52760051 | Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy. |
| Q91938514 | Engineering State-of-the-Art Plasmonic Nanomaterials for SERS-Based Clinical Liquid Biopsy Applications |
| Q58602903 | Enhanced detection of circulating tumor DNA by fragment size analysis |
| Q52632729 | Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. |
| Q61799424 | Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy |
| Q98158687 | Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR |
| Q55023743 | Evaluation of pre-analytical factors affecting plasma DNA analysis. |
| Q47099537 | Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. |
| Q92255622 | Extracellular Vesicles in Non-Small-Cell Lung Cancer: Functional Role and Involvement in Resistance to Targeted Treatment and Immunotherapy |
| Q97596503 | Feasibility of methylated ctDNA detection in plasma samples of oropharyngeal squamous cell carcinoma patients |
| Q90380066 | Fragment Enrichment of Circulating Tumor DNA With Low-Frequency Mutations |
| Q93000939 | Fragmentation patterns of circulating cell-free DNA demonstrate biomarker potential for human cancers |
| Q50107045 | From genetics to the clinic: a translational perspective on follicular lymphoma. |
| Q52619254 | Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis. |
| Q57106917 | Genetics and biology of prostate cancer |
| Q92382891 | Genome-wide cell-free DNA fragmentation in patients with cancer |
| Q96127680 | Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring |
| Q92264438 | Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma |
| Q64107530 | Genomic Testing for Human Health and Disease Across the Life Cycle: Applications and Ethical, Legal, and Social Challenges |
| Q52637922 | Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. |
| Q92830555 | Genomics-Enabled Precision Medicine for Cancer |
| Q92735765 | Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma |
| Q91807793 | Graphene Oxide-Based Biosensors for Liquid Biopsies in Cancer Diagnosis |
| Q58693928 | High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study |
| Q91452763 | High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants |
| Q59330098 | Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR |
| Q99408657 | Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma |
| Q98188951 | Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing |
| Q92589590 | Hypoxia differently modulates the release of mitochondrial and nuclear DNA |
| Q90480845 | Identification of circulating tumor DNA using a targeted 545-gene next generation sequencing panel in patients with gastric cancer |
| Q92373963 | Identification of single nucleotide variants using position-specific error estimation in deep sequencing data |
| Q91812593 | Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion |
| Q91650586 | Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer |
| Q39304648 | Implementing liquid biopsies into clinical decision making for cancer immunotherapy |
| Q91162956 | Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA |
| Q47563363 | Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System? |
| Q90662922 | Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection |
| Q42925962 | Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors |
| Q90067950 | Investigation of Preanalytical Variables Impacting Pathogen Cell-Free DNA in Blood and Urine |
| Q91145144 | Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial |
| Q52318134 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. |
| Q89620002 | Leukobiopsy - A Possible New Liquid Biopsy Platform for Detecting Oncogenic Mutations |
| Q90346406 | Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma |
| Q92544391 | Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease |
| Q58704141 | Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring |
| Q58701272 | Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy |
| Q47153925 | Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology |
| Q92454918 | Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri |
| Q93042360 | Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA) |
| Q92154338 | Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges |
| Q57114997 | Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond |
| Q90286090 | Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors |
| Q57174640 | Liquid biopsies for management of pancreatic cancer |
| Q99582650 | Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies? |
| Q48098593 | Liquid biopsy and its role in an advanced clinical trial for lung cancer |
| Q58695249 | Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology |
| Q94606175 | Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing |
| Q92861259 | Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers |
| Q58804436 | Lung adenocarcinoma patient progression with gastrointestinal metastasis response to subsequent tyrosine kinase inhibitors (TKIs) from re-biopsy of new occurring driver gene mutation |
| Q92827509 | Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA |
| Q48510203 | Magnetic Nanowire Networks for Dual-Isolation and Detection of Tumor-Associated Circulating Biomarkers |
| Q90226469 | Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice |
| Q58615751 | Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models |
| Q47569690 | Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. |
| Q57280616 | Medical research: Personalized test tracks cancer relapse |
| Q52605943 | Modularized Extracellular Vesicles: The Dawn of Prospective Personalized and Precision Medicine. |
| Q88225399 | Molecular Profiling of Liquid Biopsy Samples for Precision Medicine |
| Q63366116 | Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’ |
| Q91842359 | Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours |
| Q58455418 | Molecular imaging and molecular diagnostics: two sides of the same coin? |
| Q100962862 | Molecular prognostication of uterine smooth muscle neoplasms: from CGH array to CINSARC signature and beyond |
| Q47425702 | Molecular roles and function of circular RNAs in eukaryotic cells |
| Q47392574 | Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine |
| Q92326347 | Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey |
| Q90354943 | Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy |
| Q89170081 | Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA |
| Q96346871 | Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays |
| Q64114350 | Multiple layers of intratumor heterogeneity: clues to clonal evolution of non-small cell lung cancer |
| Q58594871 | Multiplex Cell-Free DNA Reference Materials for Quality Control of Next-Generation Sequencing-Based Diagnostic Tests of Colorectal Cancer Tolerance |
| Q56688655 | Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification |
| Q60920322 | Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma |
| Q47166342 | Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. |
| Q90400279 | Mutational analysis on gastric, duodenal, bone, and mediastinal lymph node metastases and blood from a case of primary lung adenocarcinoma |
| Q100958822 | Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma |
| Q57785739 | Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow |
| Q59329510 | New insights into structural features and optimal detection of circulating tumor DNA determined by single-strand DNA analysis |
| Q60920792 | Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA |
| Q47138927 | Next generation sequencing: clinical applications in solid tumours |
| Q104471011 | Next-Generation Liquid Biopsies: Embracing Data Science in Oncology |
| Q92348710 | Next-generation sequencing in liquid biopsy: cancer screening and early detection |
| Q92823613 | Non-invasive characterization of human bone marrow stimulation and reconstitution by cell-free messenger RNA sequencing |
| Q54940588 | Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. |
| Q47936526 | Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies |
| Q91238291 | Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients |
| Q91680060 | Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations |
| Q92015499 | Opportunities and challenges of circulating biomarkers in neuroblastoma |
| Q93064238 | Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA |
| Q49723005 | PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer |
| Q93120565 | PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study |
| Q89497134 | Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients |
| Q90664762 | Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications |
| Q48194423 | Patient monitoring through liquid biopsies using circulating tumor DNA. |
| Q98186316 | Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors |
| Q49834010 | Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests |
| Q60303017 | Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms? |
| Q96577047 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q40991086 | Personalized medicine could transform healthcare |
| Q49545117 | Personalized medicine for non-small cell lung cancer: where are we now and where can we go? |
| Q91651645 | Perspectives of the Application of Liquid Biopsy in Colorectal Cancer |
| Q89602779 | Post-mortem Plasma Cell-Free DNA Sequencing: Proof-of-Concept Study for the "Liquid Autopsy" |
| Q98288342 | Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice |
| Q100764047 | Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies |
| Q55012383 | Precision Medicine in Head and Neck Cancer: Myth or Reality? |
| Q90057486 | Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics |
| Q92841164 | Precision medicine for gastrointestinal cancer: Recent progress and future perspective |
| Q40169633 | Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'. |
| Q92041364 | Prenatal maternal biomarkers for the early diagnosis of congenital malformations: A review |
| Q89285313 | Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival |
| Q93023786 | Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA |
| Q45901388 | Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. |
| Q102059890 | Prognosis of metastasis based on age and serum analytes after follow-up of non-metastatic lung cancer patients |
| Q90388518 | Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma |
| Q89994366 | Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma |
| Q57106079 | Progress in adjuvant systemic therapy for breast cancer |
| Q50106233 | Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer |
| Q64269953 | Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group |
| Q49826552 | Quantification of Plasma Cell-Free Circulating DNA at Different Stages of Colorectal Cancer. |
| Q97523774 | Quantitative characterization of tumor cell-free DNA shortening |
| Q92512571 | RNA sequencing and swarm intelligence-enhanced classification algorithm development for blood-based disease diagnostics using spliced blood platelet RNA |
| Q53688649 | Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. |
| Q52665401 | Recent Advances in Exosomal Protein Detection Via Liquid Biopsy Biosensors for Cancer Screening, Diagnosis, and Prognosis. |
| Q46294352 | Recent progress in nucleic acids isotachophoresis |
| Q89848852 | Refining Cancer Management Using Integrated Liquid Biopsy |
| Q89520881 | Restaging after chemoradiotherapy for locally advanced esophageal cancer |
| Q90664778 | Review ctDNA and Breast Cancer |
| Q54340242 | Role of circulating tumor DNA in the management of early-stage lung cancer. |
| Q92134595 | Role of liquid biopsy in oncogene-addicted non-small cell lung cancer |
| Q90163791 | Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion |
| Q87898580 | Screening auf okkulte Neoplasien bei Patienten mit unprovozierter venöser Thromboembolie |
| Q89563984 | Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible? |
| Q89977082 | Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer |
| Q49216736 | Serum DNA integrity index as a potential molecular biomarker in endometrial cancer |
| Q57824704 | Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA |
| Q60947524 | Single-cell analysis of tumors: Creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells |
| Q92721586 | Single-molecule detection of cancer mutations using a novel PCR-LDR-qPCR assay |
| Q92063441 | Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing |
| Q64230096 | Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA |
| Q92860192 | Surface Plasmon Resonance for Biomarker Detection: Advances in Non-invasive Cancer Diagnosis |
| Q47725182 | Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. |
| Q60301211 | TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting |
| Q91372433 | Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology |
| Q93117779 | Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients |
| Q49616528 | Targeting minimal residual disease: a path to cure? |
| Q61801746 | Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitor Assay |
| Q58578019 | Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management |
| Q64232068 | The Dynamic Use of Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients |
| Q49722631 | The Role of Circulating Tumor DNA in Renal Cell Carcinoma |
| Q91713922 | The Translational Potential of Electrochemical DNA-Based Liquid Biopsy |
| Q48143437 | The Value of Cell-free DNA for Molecular Pathology |
| Q46112070 | The bridge between transplantation and regenerative medicine: Beginning a new Banff classification of tissue engineering pathology |
| Q47825070 | The clinical characteristics and prognostic analysis of Chinese advanced NSCLC patients based on circulating tumor DNA sequencing. |
| Q49220712 | The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer |
| Q49256246 | The dawn of the liquid biopsy in the fight against cancer |
| Q64078507 | The emerging role of cell-free DNA as a molecular marker for cancer management |
| Q104060436 | The future of liquid biopsy |
| Q38683944 | The future of oncology therapeutics. |
| Q92387122 | The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review |
| Q95582765 | The potential for liquid biopsies in head and neck cancer |
| Q92463703 | The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy |
| Q55269325 | The potential of liquid biopsies for the early detection of cancer. |
| Q94550861 | The untapped potential of ascites in ovarian cancer research and treatment |
| Q90438824 | The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients |
| Q55314072 | The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. |
| Q92083549 | Thermal Liquid Biopsy (TLB): A Predictive Score Derived from Serum Thermograms as a Clinical Tool for Screening Lung Cancer Patients |
| Q75721084 | Thermodynamics and kinetics guided probe design for uniformly sensitive and specific DNA hybridization without optimization |
| Q52597787 | Too many targets, not enough patients: rethinking neuroblastoma clinical trials. |
| Q93080796 | Towards Circulating-Tumor DNA-Based Precision Medicine |
| Q90447337 | Towards clinical implementation of circulating cell-free DNA in precision medicine |
| Q96576991 | Towards multi-cancer screening using liquid biopsies |
| Q64101409 | Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy |
| Q90724935 | Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements |
| Q95282127 | Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference |
| Q91943295 | Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis |
| Q91474691 | Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma |
| Q91704928 | Tumor microenvironment complexity and therapeutic implications at a glance |
| Q93040540 | Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients |
| Q102061305 | Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability |
| Q47558605 | Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling. |
| Q58599071 | Universal cancer screening: revolutionary, rational, and realizable |
| Q92914475 | Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells |
| Q92642250 | Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment |
| Q47564108 | Urine test for EGFR analysis in patients with non-small cell lung cancer |
| Q93098017 | Urine-Based Liquid Biopsy for Nonurological Cancers |
| Q90270224 | Using Class-Specific Feature Selection for Cancer Detection with Gene Expression Profile Data of Platelets |
| Q89823370 | Using gold nanoparticles to detect single-nucleotide polymorphisms: toward liquid biopsy |
| Q59789710 | Utility of "liquid biopsy" using pancreatic juice for early detection of pancreatic cancer |
| Q57044038 | Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection |
| Q58803568 | Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients |
| Q91997710 | Vessel co-option in cancer |
| Q57028649 | What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials? |
| Q64093762 | Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary Lesions |
| Q47216527 | Whole-body PET/MRI of Pediatric Patients: The Details That Matter |
| Q91326771 | Will liquid biopsies improve outcomes for patients with small-cell lung cancer? |
| Q97424206 | ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper |
| Q91452041 | ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab |
Search more.